Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 1
2001 2
2003 1
2004 4
2007 1
2009 4
2010 5
2011 4
2012 6
2013 13
2014 12
2015 21
2016 19
2017 12
2018 8
2019 8
2020 11
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

122 results
Results by year
Filters applied: . Clear all
Page 1
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodríguez-Perales S, Torres-Ruiz R, Manyam GC, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkær K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH. Xu-Monette ZY, et al. Among authors: dybkaer k. Cancer Immunol Res. 2019 Apr;7(4):644-657. doi: 10.1158/2326-6066.CIR-18-0439. Epub 2019 Feb 11. Cancer Immunol Res. 2019. PMID: 30745366 Free article.
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M, Xu-Monette ZY, Pham LV, Wang X, Tzankov A, Fang X, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Hagemeister F, van Krieken JH, Piris MA, Winter JN, Li Y, Xu B, Liu P, Young KH. Deng M, et al. Among authors: dybkaer k. Mol Cancer Res. 2021 Feb;19(2):249-260. doi: 10.1158/1541-7786.MCR-20-0466. Epub 2020 Nov 5. Mol Cancer Res. 2021. PMID: 33154093
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.
Xu-Monette ZY, Zhang H, Zhu F, Tzankov A, Bhagat G, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Hagemeister FB, Shahbaba B, De Dios I, Zhang H, Li Y, Xu B, Albitar M, Young KH. Xu-Monette ZY, et al. Among authors: dybkaer k. Blood Adv. 2020 Jul 28;4(14):3391-3404. doi: 10.1182/bloodadvances.2020001949. Blood Adv. 2020. PMID: 32722783 Free PMC article.
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, Fang X, Bhagat G, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Choi WWL, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Hagemeister F, Alinari L, Li Y, Andreeff M, Xu B, Young KH. Deng M, et al. Among authors: dybkaer k. J Hematol Oncol. 2020 Nov 4;13(1):148. doi: 10.1186/s13045-020-00982-3. J Hematol Oncol. 2020. PMID: 33148342 Free PMC article.
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Slack GW, Gascoyne RD, Tu M, Variakojis D, Chen W, Go RS, Piris MA, Møller MB, Medeiros LJ, Young KH. Hu S, et al. Among authors: dybkaer k. Blood. 2013 May 16;121(20):4021-31; quiz 4250. doi: 10.1182/blood-2012-10-460063. Epub 2013 Feb 28. Blood. 2013. PMID: 23449635 Free PMC article.
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Xu-Monette ZY, Li J, Xia Y, Crossley B, Bremel RD, Miao Y, Xiao M, Snyder T, Manyam GC, Tan X, Zhang H, Visco C, Tzankov A, Dybkaer K, Bhagat G, Tam W, You H, Hsi ED, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Winter JN, Medeiros JT, Xu B, Li Y, Kirsch I, Young KH. Xu-Monette ZY, et al. Among authors: dybkaer k. J Immunother Cancer. 2019 Oct 22;7(1):272. doi: 10.1186/s40425-019-0730-x. J Immunother Cancer. 2019. PMID: 31640780 Free PMC article.
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhao X, Winter JN, Zhang M, Li L, Møller MB, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH. Hu S, et al. Among authors: dybkaer k. Blood. 2013 Apr 4;121(14):2715-24. doi: 10.1182/blood-2012-10-461848. Epub 2013 Jan 23. Blood. 2013. PMID: 23343832 Free PMC article.
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.
Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, Geng H, Deffenbacher K, Smith L, Dybkaer K, Nakamura S, Seto M, Delabie J, Berger F, Loong F, Au WY, Ko YH, Sng I, Armitage JO, Chan WC; International Peripheral T-Cell Lymphoma Project. Iqbal J, et al. Among authors: dybkaer k. Blood. 2010 Feb 4;115(5):1026-36. doi: 10.1182/blood-2009-06-227579. Epub 2009 Nov 18. Blood. 2010. PMID: 19965671 Free PMC article.
122 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page